1201 Orange Street
Wilmington, DE 19801
|Mr. Stephen H. Willard Esq.||CEO & Director||501.19k||N/A||1961|
|Dr. Jonathan C. Javitt M.D., M.P.H.||Co-Founder, Chief Scientist Officer & Director||926.01k||N/A||1957|
|Dr. Seth L. Van Voorhees Ph.D.||CFO & Treasurer||399.96k||N/A||1961|
|Mr. Riccardo Panicucci Ph.D.||Chief Technology Officer||220k||N/A||1962|
|Suzanne Messere||Investor Relations||N/A||N/A||N/A|
|Dr. Michael Kunz||Gen. Counsel & Corp. Sec.||N/A||N/A||1965|
|Dr. Philip T. Lavin Ph.D.||Chief Methodologist||N/A||N/A||1947|
|Dr. Dennis K. McBride Ph.D.||Chief Strategy Officer & Sr. Scientist||N/A||N/A||N/A|
|Mr. Matthew Patrick Duffy||Chief Bus. Officer||N/A||N/A||1963|
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.